Objects
Lizak, Nathaniel, Hodgkinson, Suzanne, Butler, Ernest, Lechner-Scott, Jeannette, Slee, Mark, McCombe, Pamela Ann, Shaw, Cameron, Skibina, Olga, Vucic, Steve, Shuey, Neil, Barnett, Michael H., Parratt, John, Butzkueven, Helmut, Jack, Dominic, Fabris, Jessica, Kalincik, Tomas. Sage; 2021. Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: an MSBase registry substudy.
Zhong, Michael, van der Walt, Anneke, Butler, Ernest, Prevost, Julie, Girard, Marc, Oh, Jiwon, Butzkueven, Helmut, Jokubaitis, Vilija, Monif, Mastura, Hodgkinson, Suzanne, Eichau, Sara, Kalincik, Tomas, Lechner-Scott, Jeannette, Buzzard, Katherine, Skibina, Olga, Van Pesch, Vincent. Sage Publications; 2023. Prediction of relapse activity when switching to cladribine for multiple sclerosis.
Daruwalla, Cyrus, Shaygannejad, Vahid, Eichau, Sara, Girard, Marc, Prat, Alexandre, Duquette, Pierre, Yamout, Bassem, Khoury, Samia J., Sajedi, Seyed Aidin, Turkoglu, Recai, Altintas, Ayse, Skibina, Olga, Ozakbas, Serkan, Buzzard, Katherine, Grammond, P, Karabudak, R, van der Walt, A, Butzkueven, H, Maimone, D, Lechner-Scott, Jeannette, Soysal, A, John, N, Prevost, J, Havrdova, Eva Kubala, Spitaleri, D, Ramo-Tello, C, Gerlach, O, Iuliano, G, Foschi, M, Ampapa, R, van Pesch, V, Barnett, M, Shalaby, N, D'hooghe, M, Horakova, Dana, Kuhle, J, Sa, MJ, Fabis-Pedrini, M, Kermode, A, Mrabet, S, Gouider, R, Hodgkinson, S, Laureys, G, Van Hijfte, L, Macdonell, R, Alroughani, Raed, Oreja-Guevara, C, Cristiano, E, McCombe, P, Sanchez-Menoyo, JL, Singhal, B, Blanco, Y, Hughes, S, Garber, J, Solaro, C, McGuigan, C, Boz, Cavit, Taylor, B, de Gans, K, Habek, M, Al-Asmi, A, Mihaela, S, Castillo Triviño, T, Al-Harbi, T, Rojas, JI, Gray, O, Khurana, D, Patti, Francesco, Van Wijmeersch, B, Grigoriadis, N, Inshasi, J, Oh, J, Aguera-Morales, E, Fragoso, Y, Moore, F, Shaw, C, Baghbanian, SM, Shuey, N, Onofrj, Marco, Willekens, B, Hardy, TA, Decoo, D, Sempere, AP, Field, D, Wynford-Thomas, R, Cunniffe, NG, Roos, I, Malpas, CB, Coles, AJ, Lugaresi, Alessandra, Kalincik, T, Brown, JWL. Sage; 2023. Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis.
Zhong, Michael, van der Walt, Anneke, Macdonell, Richard, Prevost, Julie, Kuhle, Jens, Laureys, Guy, Van Hijfte, Liesbeth, Alroughani, Raed, Kermode, Allan G., Butler, Ernest, Barnett, Michael, Eichau, Sara, Stankovich, Jim, van Pesch, V, Grammond, P, McCombe, P, Karabudak, R, Duquette, P, Girard, M, Taylor, B, Yeh, W, Monif, M, Gresle, M, Kalincik, Tomas, Butzkueven, H, Jokubaitis, VG, Buzzard, Katherine, Skibina, Olga, Boz, Cavit, Hodgkinson, Suzanne, Slee, Mark, Lechner-Scott, Jeanette. Sage Publications; 2022. Prediction of multiple sclerosis outcomes when switching to ocrelizumab.
Zhu, Chao, Zhou, Zhen, Roos, Izanne, Merlo, Daniel, Kalincik, Tomas, Ozakbas, Serkan, Skibina, Olga, Kuhle, Jens, Hodgkinson, Suzanne, Boz, Cavit, Alroughani, Raed, Lechner-Scott, Jeannette, Barnett, Michael, Izquierdo, Guillermo, Prat, Alexandre, Horakova, Dana, Havrdova, Eva Kubala, Macdonell, Richard, Patti, Francesco, Khoury, Samia Joseph. BMJ Group; 2022. Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis.
Malpas, Charles B., Roos, Izanne, Havrdova, Eva Kubala, Izquierdo, Guillermo, Eichau, Sara, Hodgkinson, Suzanne, Grammond, Pierre, Lechner-Scott, Jeannette, Kalincik, Tomas, MSBase Study Group,, Sharmin, Sifat, Buzzard, Katherine, Skibina, Olga, Butzkueven, Helmut, Kappos, Ludwig, Patti, Francesco, Alroughani, Raed, Horakova, Dana. Springer; 2022. Multiple Sclerosis Relapses Following Cessation of Fingolimod.
Roos, Izanne, Hughes, Stella, van der Walt, Anneke, Butzkueven, Helmut, Lechner-Scott, Jeannette, Kuhle, Jens, Terzi, Murat, Laureys, Guy, Van Hijfte, Liesbeth, John, Nevin, Grammond, Pierre, Grand'Maison, Francois, McDonnell, Gavin, Soysal, Aysun, Jensen, AV, Rasmussen, PV, Svendsen, KB, Barzinji, I, Nielsen, HH, Sejbæk, T, Prakash, S, Stilund, MLM, Weglewski, A, Malpas, Charles B., Issa, NM, Kant, M, Sellebjerg, F, Gray, O, Magyari, M, Kalincik, T, MSBase Study GroupDanish MS Registry Study Group,, Sharmin, Sifat, Boz, Cavit, Alroughani, Raed, Ozakbas, Serkan, Buzzard, Katherine, Skibina, Olga. Amercian Medical Association; 2023. Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis.
Zhu, Chao, Kalincik, Tomas, Patti, Francesco, Grand'Maison, Francois, Hodgkinson, Suzanne, Grammond, Pierre, Lechner-Scott, Jeannette, Butler, Ernest, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Macdonell, Richard A. L., Horakova, Dana, Weinstock-Guttman, B, Ozakbas, S, Slee, M, Sa, MJ, Van Pesch, V, Barnett, M, Van Wijmeersch, B, Gerlach, O, Prevost, J, Terzi, M, Zhou, Zhen, Boz, C, Laureys, G, Van Hijfte, L, Kermode, AG, Garber, J, Yamout, B, Khoury, SJ, Merlo, D, Monif, M, Jokubaitis, V, Buzzard, Katherine, van der Walt, A, Butzkueven, H, MSBase, SG, Skibina, Olga, Alroughani, Raed, Izquierdo, Guillermo, Eichau, Sara, Kuhle, Jens. American Medical Association (AMA); 2023. Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation.
Foong, Yi Chao, Merlo, Daniel, Patti, Francesco, Grammond, Pierre, Amato, Maria Pia, Kalincik, Tomas, Horakova, Dana, Kubala Havrdova, Eva, Weinstock-Guttman, Bianca, Lechner Scott, Jeanette, Boz, Cavit, Sa, Maria, Gresle, Melissa, Butzkueven, H, van der Walt, A, Zhu, C, MSBASE study group,, Buzzard, Katherine, Zhong, Michael, Yeh, Wei Zhen, Jokubaitis, Vilija, Monif, Mastura, Skibina, Olga, Ozakbas, Serkan. BMJ Group; 2024. Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60.